Shattuck Labs(STTK) - 2022 Q4 - Earnings Call Transcript

First, PLD causes immunogenic cell death of ovarian cancer cells and was shown to enhance antitumor activity when combined with 154 in preclinical studies. Second, PLD is a standard-of-care in the platinum-resistant setting and is well-known that patients treated with PLD have an objective response rate in the range of 10% to 12% from multiple Phase 3 clinical trials. Thus, this was a mechanistically driven combination strategy where we do not expect difficulty determining the contribution of 154 and the re ...